Oxford Asset Management LLP Has $1.77 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Oxford Asset Management LLP boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 257.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,219 shares of the company's stock after buying an additional 8,804 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Oxford Asset Management LLP's investment portfolio, making the stock its 10th largest position. Oxford Asset Management LLP's holdings in Johnson & Johnson were worth $1,767,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,390,037,000. Raymond James Financial Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at $1,339,878,000. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the last quarter. Finally, Amundi lifted its position in Johnson & Johnson by 16.2% during the fourth quarter. Amundi now owns 11,930,183 shares of the company's stock valued at $1,698,984,000 after purchasing an additional 1,660,458 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.78 during midday trading on Monday, reaching $155.36. The company's stock had a trading volume of 5,799,419 shares, compared to its average volume of 7,920,029. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $373.81 billion, a PE ratio of 23.36, a P/E/G ratio of 2.56 and a beta of 0.49. The stock has a fifty day moving average of $159.48 and a 200 day moving average of $154.80.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.